SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer

A Phase II Trial of Atezolizumab and Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer


  • Org Study ID: HCRN GU15-215
  • Secondary ID:
  • NCT ID: NCT03272217
  • NCT Alias: NCT03133390
  • Sponsor: Arjun Balar, MD - Other
  • Source: Hoosier Cancer Research Network

Brief Summary

This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.

Detailed Description


This is a multi-center trial.

INVESTIGATIONAL TREATMENT:

Eligible patients will be receive atezolizumab 1200 mg IV flat dose plus bevacizumab 15 mg/kg
IV every 21 days

21 days equals 1 cycle of therapy and patients will be eligible to continue treatment until
progressive disease by RECIST v1.1 or unacceptable toxicity for up to 24 months.

To demonstrate adequate organ function, all screening labs must be obtained within 14 days
prior to Cycle 1 Day 1 (C1D1) of treatment:

Hematological:

- Absolute Neutrophil Count (ANC): ≥ 1,000 K/mm^3

- Hemoglobin (Hgb): ≥ 9.0 g/dL

- Absolute Lymphocyte Count: ≥ 500/uL

- Platelet Count: ≥ 100,000/uL

Renal:

- Calculated Creatinine Clearance: serum creatinine < 2.0 or ≥ 30 cc/min using a direct
method or the Cockcroft-Gault formula

- Urinary Albumin Excretion: < 1.0 g/24 hours (as estimated by urine protein-creatinine
ratio)

Hepatic:

- Bilirubin: ≤ 1.5 × upper limit of normal (ULN) (patients with known Gilbert's Disease
who have serum bilirubin ≤ 3.0 x ULN may be enrolled)

- Aspartate aminotransferase (AST): ≤ 2.5 × ULN (5.0 x ULN if liver involvement)

- Alanine aminotransferase (ALT): ≤ 2.5 × ULN (5.0 x ULN if liver involvement)

- Serum Albumin: ≥ 2.5 g/dL

Coagulation:

- International Normalized Ratio (INR) or Prothrombin Time (PT); Activated Partial
Thromboplastin Time (aPTT): ≤ 1.5 × ULN (NOTE: This applies only to patients who are not
receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation
should be on a stable dose)

Overal Status Start Date Phase Study Type
Recruiting September 13, 2017 Phase 2 Interventional

Primary Outcomes:

Primary Outcome 1 - Measure: Overall survival (OS)

Primary Outcome 1 - Time Frame: date at time of randomization up to 1 year

Condition:

  • Urothelial Carcinoma

Eligibility

Criteria:
INCLUSION CRITERIA

Patient must meet all of the following applicable inclusion criteria to participate in this
study:

- Written informed consent and Health Insurance Portability and Accountability Act of
1996 (HIPAA) authorization for release of personal health information.

- As determined by the enrolling physician or protocol designee, ability of the patient
to understand and comply with study procedures for the entire length of the study

- Age ≥ 18 years at the time of consent

- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2 within 28
days prior to randomization

- Histological or cytological evidence urothelial (transitional cell) carcinoma of the
renal pelvis, ureter, bladder or urethra

- Locally advanced/unresectable disease as determined by site attending urologic
oncologist or metastatic disease

- Evaluable untreated tumor tissue for biomarker analysis. Untreated tumor tissue is
defined as no intervening intravesical or systemic therapy since acquisition. Patients
without tissue available must be willing and safe to undergo biopsy repeat biopsy
(core needle or excisional) prior to enrollment. Subjects with < 25 slides may be
enrolled after discussion with the sponsor-investigator or co-investigator.

- Willing to undergo a core needle or excisional biopsy on-treatment. Patients will be
assessed at the time of biopsy for safety of undergoing the procedure

- Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST)
v1.1 within 28 days prior to randomization

- No prior chemotherapy for locally advanced or metastatic urothelial cancer

- Perioperative chemotherapy previously administered in the neoadjuvant and/or
adjuvant setting is permitted

- Prior chemotherapy administered in the context of chemoradiation as definitive
treatment for bladder preservation is also permitted, provided that disease
progression outside the prior radiotherapy field is demonstrated histologically
or cytologically

- Ineligible for cisplatin as defined by presence of one or more of the following:

- (Impaired renal function [GFR ≥ 30 but ≤ 60 cc/min]. Glomerular filtration rate
(GFR) should be assessed by direct measurement [i.e., creatinine clearance or
ethylenediaminetetra-acetate] or, if not available, by calculation from
serum/plasma creatinine by Cockroft-Gault equation)

- Grade ≥ 2 Hearing Loss (hearing loss measured by audiometry of 25 dB at two
contiguous frequencies)

- Grade ≥ 2 peripheral neuropathy

- ECOG Performance Status of 2

- Solitary Kidney

- If palliative radiotherapy administered, completion of palliative radiation therapy ≥
2 weeks prior to Cycle 1 Day 1 of protocol therapy

- Females of childbearing potential must have a negative serum pregnancy test within 28
days prior to registration.

- Females of childbearing potential and males must be willing to abstain from
heterosexual activity or to use 2 forms of effective methods of contraception from the
time of informed consent until 150 days (5 months) after discontinuation of
atezolizumab. For subjects randomized to receive bevacizumab the time frame is from
the time of informed consent until 180 days (6 months) after discontinuation of
bevacizumab. . The two contraception methods can be comprised of two barrier methods,
or a barrier method plus a hormonal method

EXCLUSION CRITERIA

Patients meeting any of the criteria below may not participate in the study:

- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3
weeks prior to initiation of study treatment; the following exceptions are allowed:

- Palliative radiotherapy for bone metastases or soft tissue lesions should be
completed > 7 days prior to baseline imaging

- Hormone-replacement therapy or oral contraceptives

- Treatment with any other investigational agent or participation in another clinical
trial with therapeutic intent within 28 days prior to enrollment

- Active or untreated central nervous system (CNS) metastases as determined by computed
tomography (CT) scan or magnetic resonance imaging (MRI) evaluation during screening
and prior radiographic assessments. Patients with treated asymptomatic CNS metastases
are eligible, provided they meet all of the following criteria:

- Evaluable or measurable disease outside the CNS

- No metastases to midbrain, pons, medulla, cerebellum, or within 10 mm of the
optic apparatus (optic nerves and chiasm)

- No history of intracranial or spinal cord hemorrhage

- No evidence of significant vasogenic edema

- No ongoing requirement for dexamethasone as therapy for CNS disease;
anticonvulsants at a stable dose allowed

- No stereotactic radiation, whole-brain radiation within 4 weeks prior to Cycle 1
Day 1

- Patients with central nervous system (CNS) metastases treated by neurosurgical
resection or brain biopsy within 3 months prior to Cycle 1 Day 1 will be excluded

- Radiographic demonstration of interim stability (i.e., no progression) between
the completion of CNS-directed therapy and the screening radiographic study

- Screening CNS radiographic study ≥ 4 weeks since completion of radiotherapy or
surgical resection and ≥ 2 weeks since discontinuation of corticosteroids

- Leptomeningeal disease

- Uncontrolled tumor-related pain

- Patients requiring pain medication must be on a stable regimen at study entry

- Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or
metastases causing nerve impingement) should be treated prior to enrollment.

- Asymptomatic metastatic lesions whose further growth would likely cause
functional deficits or intractable pain (e.g., epidural metastasis that is not
currently associated with spinal cord compression) should be considered for
loco-regional therapy if appropriate prior to enrollment.

- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
drainage procedures (once monthly or more frequently)

- Patients with indwelling drainage catheters are allowed.

- Uncontrolled hypercalcemia (> 1.5 mmol/L ionized calcium or Ca > 12 mg/dL or corrected
serum calcium > ULN) or symptomatic hypercalcemia requiring continued use of
bisphosphonate therapy or denosumab.

- Patients who are receiving bisphosphonate therapy or denosumab specifically to
prevent skeletal events and who do not have a history of clinically significant
hypercalcemia are eligible.

- Patients who are receiving denosumab prior to enrollment must be willing and
eligible to receive a bisphosphonate instead while in the study.

- Malignancies other than urothelial cancer within 5 years prior to Cycle 1 Day 1, with
the exception of those with a negligible risk of metastasis or death treated with
expected curative outcome (such as adequately treated carcinoma in situ of the cervix,
basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically
with curative intent) or localized prostate cancer treated with curative intent and
absence of prostate-specific antigen (PSA) relapse or incidental prostate cancer
(T1/T2a, Gleason score ≤ 3 + 4, and PSA ≤ 0.5 ng/mL undergoing active surveillance and
treatment naive)

- Pregnant or breastfeeding

- History of severe allergic, anaphylactic, or other hypersensitivity reactions to
chimeric or humanized antibodies or fusion proteins

- Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster
ovary cells or any component of the atezolizumab or bevacizumab formulation

- History of autoimmune disease, including but not limited to myasthenia gravis,
myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
inflammatory bowel disease, vascular thrombosis associated with anti-phospholipid
syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, Guillain-Barré
syndrome, multiple sclerosis, vasculitis, or glomerulonephritis

- Subjects with a history of autoimmune-related hypothyroidism on a stable dose of
thyroid replacement hormone may be eligible for this study.

- Subjects with controlled Type I diabetes mellitus on a stable dose of insulin
regimen may be eligible for this study.

- Subjects with a history of celiac disease may be eligible if controlled with
diet.

- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
pneumonitis on screening chest CT scan

- History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

- History of confirmed positive test for human immunodeficiency virus (HIV)

- Patients with active hepatitis B virus (HBV) (chronic or acute, defined as having a
positive hepatitis B surface antigen [HBsAg] test at screening) or hepatitis C virus
(HCV)

- Patients with past HBV infection or resolved HBV infection (defined as the
presence of hepatitis B core antibody [HBc Ab] and absence of HBsAg) are eligible

- Patients positive for HCV antibody are eligible only if polymerase chain reaction
is negative for HCV RNA

- Active tuberculosis

- Severe infections within 4 weeks prior to Cycle 1 Day 1, including but not limited to
hospitalization for complications of infection, bacteremia, or severe pneumonia

- Signs or symptoms of active infection within 2 weeks prior to C1D1

- Received therapeutic oral or IV antibiotics within 1 week prior to C1D1

- Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary
tract infection or to prevent chronic obstructive pulmonary disease exacerbation)
are eligible

- New York Heart Association Congestive Heart Failure Class II or greater

- Myocardial infarction, unstable angina or unstable arrhythmias within 3 months of
enrollment.

- History of stroke or TIA within 3 months of enrollment

- Other clinically significant arterial vascular disease within 6 months of enrollment
(e.g. aortic aneurysm requiring surgical repair or recent peripheral arterial
thrombosis). Prior history of adequately treated venous thromboembolism > 7 days prior
to C1D1 on stable dose of therapeutic anticoagulation is permitted

- Patients with known coronary artery disease, congestive heart failure not meeting the
above criteria, or left ventricular ejection fraction < 50% must be on a stable
medical regimen that is optimized in the opinion of the treating physician, in
consultation with a cardiologist if appropriate.

- Major surgical procedure other than for diagnosis within 28 days prior to C1D1 or
anticipation of need for a major surgical procedure during the course of the study

- Prior allogeneic stem cell or solid organ transplant

- Administration of a live, attenuated vaccine within 4 weeks before C1D1 or
anticipation that such a live attenuated vaccine will be required during the study

- Influenza vaccination should be given during influenza season only (approx. Oct.
to Mar.). Patients must not receive live, attenuated influenza vaccine (e.g.,
FluMist®) within 4 weeks prior to C1D1 or at any time during the study

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or render the subject at high risk from treatment
complications

ATEZOLIZUMAB-SPECIFIC EXCLUSION CRITERIA:

- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including
anti−CTLA-4, anti−PD-1, and anti−PD-L1 therapeutic antibodies

- Prior cancer vaccines and cellular immunotherapy are permitted.

- Treatment with systemic immunostimulatory agents (including but not limited to IFNs,
interleukin [IL]-2) within 6 weeks or five half-lives of the drug, whichever is
shorter, prior to C1D1

- Treatment with systemic corticosteroids or other systemic immunosuppressive
medications (including but not limited to prednisone, dexamethasone, cyclophosphamide,
azathioprine, methotrexate, thalidomide, and anti−tumor necrosis factor [anti-TNF]
agents) within 2 weeks prior to C1D1, or anticipated requirement for systemic
immunosuppressive medications during the trial

- Patients who have received acute, low-dose, systemic immunosuppressant
medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled

- The use of inhaled corticosteroids, physiologic replacement doses of
glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g.,
fludrocortisone for adrenal insufficiency) is allowed

BEVACIZUMAB-SPECIFIC EXCLUSION CRITERIA:

- Inadequately controlled hypertension (defined as persistent systolic blood pressure
(SBP) > 150 and/or diastolic blood pressure (DBP) > 100 mmHg)

- Prior history of hypertensive crisis or hypertensive encephalopathy

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

- Current or recent (within 10 days of study enrollment) use of aspirin (> 325 mg/day),
clopidogrel (> 75 mg/day), or current or recent (within 10 days prior to first dose of
bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic
agents for therapeutic purposes

- History of hemoptysis (≥ 1/2 teaspoon of bright red blood per episode) within 1 month
of study enrollment

- Minor surgical procedure within 7 calendar days prior to C1D1

- History of abdominal or tracheoesophageal fistula or gastrointestinal perforation
within 6 months prior to enrollment

- Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine
parenteral hydration, parenteral nutrition, or tube feeding

- Evidence of abdominal free air not explained by paracentesis or recent surgical
procedure

- Serious non-healing or dehiscing wound, active ulcer, or untreated or non-healing bone
fracture

- On-going gross hematuria associated with clots
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

Official Information

Name: Arjun Balar, M.D.

Role: Study Chair

Affiliation: Hoosier Cancer Research Network

Overall Contact

Name: Dylan Cregar

Phone: 317.634.5842

Email: dcregar@hoosiercancer.org

Link: Hoosier Cancer Research Network Website

Locations

Facility Status Contact
University of Arizona at Dignity Health St. Joseph
Phoenix, Arizona 85004
United States
Recruiting Stephanie Wilson
520-626-2548
swilson481@email.arizona.edu
HealthPartners Institute
Minneapolis, Minnesota 55440
United States
Recruiting Jennifer Collier
651-254-3391
Jennifer.Collier@parknicollet.com
New York University Clinical Cancer Center
New York, New York 10016
United States
Recruiting Karen Martirosyan
212-263-4434
Karen.martirosyan@nyumc.org
Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Recruiting Ashley Regazzi
646-227-2178
regazzia@mskcc.org
West Cancer Center University of Tennessee
Memphis, Tennessee 38120
United States
Recruiting Rachel Adams
901-683-0055
raadams@WESTCLINIC.com
Froedtert & The Medical College of Wisconsin
Milwaukee, Wisconsin 53226
United States
Recruiting Stacey Zindars
414-805-8913
szindars@mcw.edu